Early results from a phase I study on orally administered tris(8-quinolinolato)gallium(III) (FFC11, KP46) in patients with solid tumors--a CESAR study (Central European Society for Anticancer Drug Research--EWIV).

Authors :: Hofheinz RD
Dittrich C
Jakupec MA
Drescher A
Jaehde U
Gneist M
Graf von Keyserlingk N
Keppler BK
Hochhaus A
Source :: International journal of clinical pharmacology and therapeutics [Int J Clin Pharmacol Ther] 2005 Dec; Vol. 43 (12), pp. 590-1.
Publication Year :: 2005

Subjects :: Administration, Oral
Antineoplastic Agents adverse effects
Dose-Response Relationship, Drug
Female
Humans
Male
Maximum Tolerated Dose
Organometallic Compounds adverse effects
Oxyquinoline adverse effects
Oxyquinoline pharmacokinetics
Societies, Scientific
Antineoplastic Agents pharmacokinetics
Neoplasms metabolism
Organometallic Compounds pharmacokinetics
Oxyquinoline analogs & derivatives

Full Text Access

Tools